ASBMT News  by unknown
BBMT IMPACT FACTOR MOVES UP
TO 3.561
Biology of Blood and Marrow
Transplantation has earned as ISI Im-
pact Factor of 3.561—its highest
since the journal was founded in
1995.
The ultimate measure of the suc-
cess of a medical journal is its actual
impact on research and clinical prac-
tice. However, in an effort to quantify
that impact, the Institute for Scientific
Information (ISI) computes and as-
signs a numerical “impact factor” to
peer-reviewed journals. The number
is based on the frequency of citations
of the journal’s articles in other scien-
tific publications in a given year .
The new impact factor moves
BBMT up to the following positions:
● 4th among 20 transplantation
journals
● 16th among 60 hematology
journals
● 28th among 114 immunology
journals
“We are very pleased with the
growth of the journal and the way it
is being cited throughout the medical
literature,” said Rob Negrin, MD,
ASBMT president. “I join with our of-
ficers and directors in congratulating
the editor-in-chief, Dr. Robert Korn-
gold, the associate editors and the
members of the journal’s editorial
board.”
FDA ASKED TO RECONSIDER RULE
ON CONTAMINATED BLOOD
The rare but occasional transplan-
tation of contaminated cellular prod-
ucts was the topic of a meeting in
June between FDA representatives
and leaders of cellular therapy orga-
nizations, including ASBMT.
Ever since the implementation of
the FDA Current Good Tissue Practice
(cGTP) rule in May last year, there has
been concern about a proscription
against the transplantation of hema-
topoietic progenitor cell products that
have positive sterility cultures.
According to a strict interpretation
of section 1271.265, distribution or
infusion of a blood product with a
positive microbial culture is a violation
of the cGTP rule. Some centers have
been reporting the transplant of pos-
itive-culture products as a deviation
under an urgent medical need ex-
emption. The FDA, however, has
maintained that permitted deviations
apply only to donor eligibility and not
to the transplant of manufactured
products that have failed a sterility
test.
Transplantation of a culture-posi-
tive autologous or allogeneic periph-
eral blood cell or donor lymphocyte
product is an unusual occurrence, ac-
cording to data in a recent survey of
members of the International Society
for Cellular Therapy (ISCT), presented
at the meeting with the FDA. How-
ever, in some situations it is accepted
clinical practice to proceed with the
infusion, according to the survey.
The staff representing the FDA Cen-
ter for Biologics Evaluation and Re-
search (CBER) acknowledged the ap-
parent disparity between clinical
practice and the cGTP rule and said
that the information presented at the
meeting would be evaluated to de-
termine whether a guidance docu-
ment or adjustment in the cGTP rule
might be needed.
STANFORD PHYSICIAN-SCIENTIST
WINS INVESTIGATOR AWARD
A physician-scientist at Stanford
University Medical School is the recip-
ient of a New Investigator Award
from ASBMT and Astellas Pharma US,
Inc.
Jing-Zhou Hou, MD, PhD, is a clin-
ical fellow in hematology in the
school’s Division of Hematology and
BMT. His research project is a preclin-
ical study of human T regulatory cells.
The $50,000 award, payable over
a two-year term, is supported by an
unrestricted educational grant from
Astellas Pharma US, Inc.
Dr. Hou will explore the molecular
mechanisms and possible clinical im-
plications of CD4CD25 T-regula-
tory cells (Tregs), thought to play an
important role in the control of graft-
versus-host disease in hematopoietic
cell transplantation.
According to Dr. Hou, Tregs in
mouse models play a critical role in
controlling GvHD and stem cell en-
graftment while preserving graft-ver-
sus-tumor activity. However, many
key questions remain, including how
sufficient numbers of Tregs can be
isolated from human for clinical use.
Using an intracellular staining assay
for FoxP3—a major transcription fac-
tor associated with Treg function—
Dr. Hou has developed strategies to
identify the CD4CD25 cells that
have regulatory function by a in vitro
mixed lymphocytes reaction (MLR) as-
say. His research will attempt to iden-
tify important receptors influencing
Treg function.
He also will look at the ways in
which Tregs interact with the immu-
nosuppressive drugs used to prevent
rejection in transplant recipients.
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